Is AEON Biopharma, Inc. (AEON) a Buy, Sell, or Hold?
AEON Biopharma, Inc.
AMEX:AEON
$0.357 USD
$0.03 (10.84%)
- Volume
- 46.92M
- Average Volume
- 81.32K
- Market Capitalization
- $4.22M
- P/E Ratio
- -0.07
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.45
- Year Low
- $0.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.99
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Robert Bancroft |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AEON |
| CUSIP | 00791X209 |
| CIK | 0001837607 |
| Web | http://www.aeonbiopharma.com |
| Phone | 949-354-6499 |
| Currency | USD |
| Employees | 8 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.16 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.99 |
| Quick Ratio | 0.99 |
| Cash Ratio | 0.94 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.99 |
| Price / Cash Flow | -0.35 |
| Price / Book | -0.26 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.95 |
| Trailing P/E Ratio | -0.07 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-39.22M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 223.66% |
| Return on Assets | -696.52% |
Financials Score
| AltmanZ Score | -87.44 |
| Piotroski Score | 2.00 |
| Working Capital | -44K |
| Total Assets | 8.63M |
| Ebit | -24.15M |
| Market Cap | 3.81M |
| Total Liabilities | 25.38M |
Poll Results
About AEON Biopharma, Inc. (AMEX:AEON) Stock
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California. ...
2026-07-14 08:00:00
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering
2026-06-04 07:00:00
IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 16:05:00
- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% - - Bolstered leadership team with appointment of John Bencich as Chief Financial Officer - IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 31, 2026, and provided a corporate update.
AEON Biopharma Sets Annual Shareholder Meeting
2026-04-24 16:05:00
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif. , April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX (onabotulinumtoxinA) to achieve full-label U.
AEON Biopharma Sets Annual Shareholder Meeting
2026-04-24 16:05:00
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company's offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
Frequently Asked Questions
-
What is the current AEON Biopharma, Inc. (AEON) stock price?
-
AEON Biopharma, Inc.(AMEX:AEON) stock price is $0.357 in the last trading session. During the trading session, AEON stock reached the peak price of $1.45 while $0.2592 was the lowest point it dropped to. The percentage change in AEON stock occurred in the recent session was 10.84% while the dollar amount for the price change in AEON stock was $0.03.
-
AEON's industry and sector of operation?
-
The AMEX listed AEON is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AEON?
-
Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary
Robert Bancroft | President, Chief Executive Officer & Director
Chad K. Oh | Chief Medical Officer
John A. Bencich | Chief Financial Officer
Jennifer Sy | Chief Accounting Officer -
How many employees does AEON have?
-
Number of AEON employees currently stands at 8. AEON operates from 4040 Macarthur Boulevard, Newport Beach, CA 92614, US.
-
Link for AEON official website?
-
Official Website of AEON is: http://www.aeonbiopharma.com
-
How do I contact AEON?
-
AEON could be contacted at phone #949-354-6499 and can also be accessed through its website. AEON operates from 4040 Macarthur Boulevard, Newport Beach, CA 92614, US.
-
How many shares of AEON are traded daily?
-
The average number of AEON shares traded daily for last 3 months was 81.32K.
-
What is the market cap of AEON currently?
-
The market value of AEON currently stands at $4.22M with its latest stock price at $0.357